Brodalumab effective in treating Plaque psoriasis, reports study
Brodalumab is a monoclonal antibody approved by the United States Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis in adult patients who have failed treatment with topical and other systemic therapy. However, There is limited real-life evidence with brodalumab in patients with plaque psoriasis in Canada.
Véronique Gaudet and team conducted a retrospective analysis to examine real-world effectiveness of brodalumab in Canadian routine care with a focus on clinician and patient-reported outcomes, as well as measuring continuation rates and persistency.
The researchers found out that Brodalumab brought out significant improvements in disease severity and patient-reported outcomes. High continuation rates were also achieved in treating plaque psoriasis. The current study is published in Journal of Cutaneous Medicine and Surgery.
Retrospective analysis was conducted on data collected through the brodalumab patient support program (PSP) in Canada for patients initiating brodalumab between June 2018 (PSP launch)- June 2020 with a minimum of 16 weeks follow-up from first dose. Effectiveness was assessed by improvements in PASI, BSA and DLQI; continuation rates and persistency on therapy were reported.
The key findings of the study are as follows
• A total of 864 patients (male, 59%; median age, 52 years) were included in the analysis. In a subset of patients with both baseline and follow-up scores, statistically significant improvements were observed.
• Both biologic-naïve and biologic-exposed patients had a statistically significant improvement in Psoriasis Area and Severity Index scores, body surface area involvement, and Dermatology Life Quality Index scores from baseline to subsequent follow-up after initiation of brodalumab.
• A high proportion of patients remained on brodalumab after 16 weeks, with similar continuation rates among biologic-naïve and biologic-exposed patients.
• PASI improved from 13.9 to 1.8, BSA improved from 16.6% to 2.5% and DLQI improved from 16.2 to 2.9. Brodalumab demonstrated high continuation rates (89.9%), with similar rates in biologic-naïve and biologic-experienced patients (92.1% and 88.6%, respectively).
• High continuation rates were also observed among patients who had previously received secukinumab or ixekizumab, other anti–IL-17 agents, as their most recent biologic treatment.
• Patients who received secukinumab or ixekizumab as their most recent biologic therapy (89.0% and 86.2%, respectively). Persistence at 6, 12, and 18 months was 82.0%, 69.9%, and 63.4%, respectively.
The researchers ended effectiveness of brodalumab was demonstrated in this Canadian routine care study, with significant improvements in disease severity and patient-reported outcomes. High continuation rates were achieved; including in patients previously treated with IL-17A inhibitors. Future studies will provide further evidence of brodalumab’s benefits for the management of plaque psoriasis in the real-world setting.
Reference: Reference: Gaudet V, Yap B, Hassan S, Barbeau M. Brodalumab for Plaque Psoriasis: A Canadian Real-World Experience at 2-Years Post-Launch. Journal of Cutaneous Medicine and Surgery. 2023;0(0). doi:10.1177/12034754231168851
Keywords: Brodalumab, Plaque psoriasis, Canadian population, topical, other systemic therapy, PASI, BSA and DLQI,biologic-naïve, biologic-exposed patients, Psoriasis Area, Severity Index scores, body surface area involvement, and Dermatology Life Quality Index scores, Journal of Cutaneous Medicine and Surgery, Véronique Gaudet.
